Target intelligence / Profile preview

Glycine-containing peptidoglycan cross-link

Molecular classification
Peptidoglycan component, Cell wall structural element, Other
01

Overview

Glycine-containing peptidoglycan cross-links are essential structural motifs in the cell walls of various Gram-positive bacteria, particularly within the genus Staphylococcus [1, 3]. These interpeptide bridges, which often consist of a pentaglycine chain, connect the L-lysine of one stem peptide to the D-alanine of another, providing the mechanical strength required to withstand high internal osmotic pressure [1, 3]. While the pentaglycine bridge is the hallmark of Staphylococcus aureus, similar glycine-rich bridges are found in non-S. aureus species such as S. epidermidis, S. simulans, and S. saprophyticus, although they may occasionally incorporate L-serine or L-alanine [1, 4]. These cross-links are the specific substrate for glycyl-glycine endopeptidases like lysostaphin and ALE-1, which cleave the peptide bonds between glycine residues [2, 4]. The targeted hydrolysis of these bridges leads to the rapid disintegration of the peptidoglycan network, resulting in bacterial lysis [2]. Consequently, these cross-links represent a vulnerable therapeutic target for treating infections caused by coagulase-negative staphylococci, which are increasingly associated with biofilm-mediated infections on medical implants [2, 3].

Other names
Peptidoglycan interpeptide bridgeGlycine-rich cross-bridgePentaglycine bridgeGlycyl-glycine cross-linkStaphylococcal interpeptide bridge
02

Mechanism of action

Hydrolysis of glycyl-glycine peptide bonds within the interpeptide bridge, leading to cell wall degradation and osmotic lysis.

03

Biological functions

Cell wall stabilizationOsmotic protectionStructural integrityPeptidoglycan cross-linking
04

Disease associations

InfectionBacteremiaSkin and soft tissue infectionMedical device-associated infection
05

Safety considerations

Immunogenicity of protein-based therapeuticsPro-inflammatory response due to rapid bacterial lysisDevelopment of resistance via bridge modification (e.g., Gly to Ser substitution)
06

Interacting drugs

Lysostaphin

4 more in the full profile.

Beyond the preview

Go deeper on Glycine-containing peptidoglycan cross-link.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycine-containing peptidoglycan cross-link.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call